Regeneron price target raised to $870 from $820 at Raymond James

Raymond James raised the firm’s price target on Regeneron (REGN) to $870 from $820 and keeps an Outperform rating on the shares. While most major contributors to the Q4 beat were known, and some may quibble with the tepid Q1 Eylea commentary, the firm thinks it’s important to look at the bigger picture. The analyst thinks the Eylea franchise, with important HD label enhancements now in place, is poised for share acceleration, and 2026 will be a key pipeline year with a number of late-stage readouts that should meaningfully diversify the commercial conversation for years to come.